Literature DB >> 29071355

Extent of Dorsolateral Prefrontal Cortex Plasticity and Its Association With Working Memory in Patients With Alzheimer Disease.

Sanjeev Kumar1,2, Reza Zomorrodi1, Zaid Ghazala1,2,3, Michelle S Goodman1,2, Daniel M Blumberger1,2,3, Amay Cheam1,2, Corinne Fischer3,4, Zafiris J Daskalakis1,2,3, Benoit H Mulsant1,2,3, Bruce G Pollock1,2,3, Tarek K Rajji1,2,3.   

Abstract

Importance: The extent of dorsolateral prefrontal cortex (DLPFC) plasticity in Alzheimer disease (AD) and its association with working memory are not known.
Objectives: To determine whether participants with AD had impaired DLPFC plasticity compared with healthy control participants, to compare working memory between participants with AD and controls, and to determine whether DLPFC plasticity was associated with working memory. Design, Setting, and Participants: This cross-sectional study included 32 participants with AD who were 65 years or older and met diagnostic criteria for dementia due to probable AD with a score of at least 17 on the Mini-Mental State Examination and 16 age-matched control participants. Participants were recruited from a university teaching hospital from May 2013 to October 2016. Main Outcomes and Measures: Plasticity of the DLPFC measured as potentiation of cortical-evoked activity using paired associative stimulation (a combination of peripheral nerve electrical stimulation and transcranial magnetic stimulation) combined with electroencephalography. Working memory was assessed with the n-back task (1- and 2-back) and measured using the A' statistic.
Results: Among the 32 participants with AD, 17 were women and 15 were men (mean [SD] age, 76.3 [6.3] years); among the 16 controls, 8 were men and 8 were women (mean [SD] age, 76.4 [5.1] years). Participants with AD had impaired DLPFC plasticity (mean [SD] potentiation, 1.18 [0.25]) compared with controls (mean [SD] potentiation, 1.40 [0.35]; F1,44 = 5.90; P = .02; between-group comparison, Cohen d = 0.77; P = .01). Participants with AD also had impaired performances on the 1-back condition (mean [SD] A' = 0.47 [0.30]) compared with controls (mean [SD] A' = 0.96 [0.01]; Cohen d = 1.86; P < .001), with similar findings for participants with AD on the 2-back condition (mean [SD] A' = 0.29 [0.2]) compared with controls (mean [SD], A' = 0.85 [0.18]; Cohen d = 2.83; P < .001). Plasticity of DLPFC was positively associated with working memory performance on the 1-back A' (parameter estimate B [SE] = 0.32 [0.13]; standardized β = 0.29; P = .02) and 2-back A' (B [SE] = 0.43 [0.15]; β = 0.39; P = .006) across both groups after controlling for age, education, and attention. Conclusions and Relevance: This study demonstrated impaired in vivo DLPFC plasticity in patients with AD. The findings support the use of DLPFC plasticity as a measure of DLPFC function and a potential treatment target to enhance DLPFC function and working memory in patients with AD.

Entities:  

Mesh:

Year:  2017        PMID: 29071355      PMCID: PMC6583382          DOI: 10.1001/jamapsychiatry.2017.3292

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  36 in total

1.  High-frequency repetitive transcranial magnetic stimulation combined with cognitive training improves cognitive function and cortical metabolic ratios in Alzheimer's disease.

Authors:  Fengxia Zhang; Yuanyuan Qin; Lingfeng Xie; Caixia Zheng; Xiaolin Huang; Min Zhang
Journal:  J Neural Transm (Vienna)       Date:  2019-07-10       Impact factor: 3.575

2.  Association of functional connectivity of the executive control network or default mode network with cognitive impairment in older adults with remitted major depressive disorder or mild cognitive impairment.

Authors:  Benoit H Mulsant; Aristotle N Voineskos; Neda Rashidi-Ranjbar; Tarek K Rajji; Colin Hawco; Sanjeev Kumar; Nathan Herrmann; Linda Mah; Alastair J Flint; Corinne E Fischer; Meryl A Butters; Bruce G Pollock; Erin W Dickie; Christopher R Bowie; Matan Soffer
Journal:  Neuropsychopharmacology       Date:  2022-04-11       Impact factor: 7.853

Review 3.  Transcranial Magnetic Stimulation in the Treatment of Neurological Diseases.

Authors:  Fahad A Somaa; Tom A de Graaf; Alexander T Sack
Journal:  Front Neurol       Date:  2022-05-20       Impact factor: 4.086

4.  rTMS for the treatment of Alzheimer's disease: where should we be stimulating?

Authors:  Alesha Heath; J L Taylor; M Windy McNerney
Journal:  Expert Rev Neurother       Date:  2018-10-29       Impact factor: 4.618

5.  Introducing a Novel Approach for Evaluation and Monitoring of Brain Health Across Life Span Using Direct Non-invasive Brain Network Electrophysiology.

Authors:  Noa Zifman; Ofri Levy-Lamdan; Gil Suzin; Shai Efrati; David Tanne; Hilla Fogel; Iftach Dolev
Journal:  Front Aging Neurosci       Date:  2019-09-09       Impact factor: 5.750

Review 6.  Modulating Frontal Networks' Timing-Dependent-Like Plasticity With Paired Associative Stimulation Protocols: Recent Advances and Future Perspectives.

Authors:  Giacomo Guidali; Camilla Roncoroni; Nadia Bolognini
Journal:  Front Hum Neurosci       Date:  2021-04-22       Impact factor: 3.169

Review 7.  Therapy for Alzheimer's disease: Missing targets and functional markers?

Authors:  Milan Stoiljkovic; Tamas L Horvath; Mihály Hajós
Journal:  Ageing Res Rev       Date:  2021-03-09       Impact factor: 11.788

Review 8.  Brain Stimulation in Alzheimer's Disease.

Authors:  Chun-Hung Chang; Hsien-Yuan Lane; Chieh-Hsin Lin
Journal:  Front Psychiatry       Date:  2018-05-22       Impact factor: 4.157

9.  Aged rhesus monkeys: Cognitive performance categorizations and preclinical drug testing.

Authors:  Marc R Plagenhoef; Patrick M Callahan; Wayne D Beck; David T Blake; Alvin V Terry
Journal:  Neuropharmacology       Date:  2021-02-06       Impact factor: 5.250

10.  Pharmacological Modulation of Long-Term Potentiation-Like Activity in the Dorsolateral Prefrontal Cortex.

Authors:  Bahar Salavati; Zafiris J Daskalakis; Reza Zomorrodi; Daniel M Blumberger; Robert Chen; Bruce G Pollock; Tarek K Rajji
Journal:  Front Hum Neurosci       Date:  2018-04-24       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.